6926.TWO Shine-On BioMedical Co.,Ltd.
- Market cap
- TWD 2.76B
- P/E
- -
- P/B
- 3.75x
- ROE
- -12.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6926.TWO undervalued?
Graham numberThe Graham number of Shine-On BioMedical Co.,Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shine-On BioMedical Co.,Ltd. fundamental analysis
No fundamental analysis for Shine-On BioMedical Co.,Ltd. yet.
Shine-On BioMedical Co.,Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shine-On BioMedical Co.,Ltd.
Shine-On BioMedical Co.,Ltd. research, develops, and manufactures anti-cancer related drug products. It also develops antibody anticancer drugs, such as exosome anti-cancer drugs, that includes SOB101 and SOB102; SOB201 for engineered multi-target exosomes; SOA101, a dual immune checkpoint T cell adapter antibody; and SOA201, a trispecific adapter immune cell antibody. Shine-On BioMedical Co.,Ltd. was founded in 2011 and is based in Taichung, Taiwan.
Full company profileShine-On BioMedical Co.,Ltd. financial statements
Shine-On BioMedical Co.,Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 9.52M | 0.00 | 30.0M |
| Gross Profit | -638K | -1.63M | 6.67M | -2.19M | 30.0M |
| Operating Income | -8.62M | -21.8M | -62.7M | -136M | -125M |
| EBITDA | -7.78M | -20.2M | -33.0M | -116M | -108M |
| Net Income | -8.43M | -19.5M | -37.2M | -119M | -110M |
| EPS | -0.19 | -0.43 | -0.75 | -2.39 | -2.21 |
| Balance Sheet | |||||
| Total Assets | 912M | 1.18B | 1.16B | 1.06B | 951M |
| Total Liabilities | 4.26M | 4.14M | 23.3M | 42.2M | 43.7M |
| Shareholders' Equity | 908M | 1.17B | 1.14B | 1.02B | 907M |
| Cash & Short-term Investments | 906M | 1.17B | 1.14B | 1.04B | 49.2M |
| Total Debt | 2.67M | 1.52M | 538K | 2.60M | - |
| Cash Flow | |||||
| Operating Cash Flow | -6.34M | -21.7M | -26.9M | -91.4M | -115M |
| Capital Expenditure | 2.96M | 2.78M | 662K | 608K | 1.04M |
| Free Cash Flow | -9.30M | -24.4M | -27.5M | -92.1M | -116M |
| Ratios | |||||
| ROE | -0.9% | -1.7% | -3.3% | -11.7% | -12.2% |
| ROA | -0.9% | -1.7% | -3.2% | -11.2% | -11.6% |
| Net Profit Margin | - | - | -390.2% | - | -367.6% |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.00x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shine-On BioMedical Co.,Ltd. dividends
Shine-On BioMedical Co.,Ltd. has not paid dividends in the last 5 fiscal years.
Who owns Shine-On BioMedical Co.,Ltd.
Ownership data of Shine-On BioMedical Co.,Ltd. is not available yet.
Shine-On BioMedical Co.,Ltd. company profile
- Company name
- Shine-On BioMedical Co.,Ltd.
- Ticker
- 6926.TWO
- ISIN
- TW0006926009
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 22
- Fiscal year end
- December
- Address
- 10F, No. 573, Taichung, Taiwan, 407569
- Phone
- 886 4 2327 2888
- Website
- shineon-bio.com
About Shine-On BioMedical Co.,Ltd.
Shine-On BioMedical Co.,Ltd. research, develops, and manufactures anti-cancer related drug products. It also develops antibody anticancer drugs, such as exosome anti-cancer drugs, that includes SOB101 and SOB102; SOB201 for engineered multi-target exosomes; SOA101, a dual immune checkpoint T cell adapter antibody; and SOA201, a trispecific adapter immune cell antibody. Shine-On BioMedical Co.,Ltd. was founded in 2011 and is based in Taichung, Taiwan.
Shine-On BioMedical Co.,Ltd. management
1- Mr. Hongzhe JiangGeneral Manager